Clinical trials: Schizophrenia
Schizophrenia
An Extension Study of Safety and Tolerability of SEP-363856 in Adult Subjects With Schizophrenia
An extension study of safety and tolerability of SEP-363856 in adult subjects with schizophrenia
- Trial name
- NCT02970929
- Testing
- SEP-363856
- Where
- 30 sites in United States, Hungary and 3 more
- Volunteers
- 157 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
A Study of the Safety, PK, and Exploratory Efficacy of SP-624 in Acutely Psychotic Adult Subjects With Schizophrenia
This is a Phase 1B clinical study evaluating the safety and exploring the effectiveness of SP-624 as compared to placebo in the treatment of adults with schizophrenia experiencing acute psychosis.
- Trial name
- NCT04510298
- Testing
- SP-624
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Sirtsei Pharmaceuticals, Inc.
Schizophrenia
Multiple Ascending Doses of PF-04958242 in Subjects With Stable Schizophrenia
This study aims to assess the safety, tolerability and pharmacokinetics of PF-04958242 in multiple ascending doses in subjects with stable schizophrenia.
- Trial name
- MAD (NCT02332798)
- Testing
- PF-04958242
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Biogen
Schizophrenia
Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.
Lurasidone HCl is a compound being developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is effective, tolerable, and safe as compared with quetiapine XR short term…
- Trial name
- PEARL 3 (NCT00790192)
- Testing
- Lurasidone, Quetiapine XR
- Where
- 65 sites in United States, India and 3 more
- Volunteers
- 488 people
- Sponsor
- Sumitomo Pharma America, Inc.
Cognitive Impairment Associated With Schizophrenia (CIAS), Cognitive Impairment
A Study to Evaluate RL-007 in the Treatment of Cognitive Impairment Associated With Schizophrenia (CIAS)
The goal of this clinical trial is to evaluate if the investigational drug, RL-007, can improve the cognitive performance of subjects with schizophrenia. The main questions the study aims to answer are: 1.
- Conditions
- Cognitive Impairment Associated With Schizophrenia (CIAS), Cognitive Impairment, Schizophrenia
- Trial name
- NCT05686239
- Testing
- RL-007 (Inidascamine)
- Where
- 36 sites in United States, Bulgaria and 2 more
- Volunteers
- 242 people
- Sponsor
- Recognify Life Sciences
Schizophrenia, Schizophrenic Disorders
Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia.
The purpose of this open-label study is to evaluate the long-term (6-month) safety and tolerability of extended-release paliperidone, an atypical antipsychotic, given in flexible dosages to adolescents with schizophrenia.
- Conditions
- Schizophrenia, Schizophrenic Disorders, Psychotic Disorders, Dementia Praecox
- Trial name
- NCT00488319
- Testing
- Paliperidone ER
- Where
- 53 sites in United States, Belgium and 9 more
- Volunteers
- 400 people
- Sponsor
- Janssen Research & Development, LLC
Schizophrenia
A Study of the Safety, Tolerability and Pharmacokientics of RO5545965 in Patients With Schizophrenia on Risperidone
This randomized, double-blinded, placebo-controlled study will investigate the safety, tolerability, and pharmacokinetics of multiple doses of RO5545965 administered orally to psychiatrically stable patients with schizophrenia…
- Trial name
- NCT02019329
- Testing
- RO5545965, risperidone
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Hoffmann-La Roche
Bipolar Disorder, Affective Disorders, Psychotic
A Study to Evaluate the Safety and Effectiveness of Topiramate Compared to Placebo in the Treatment of Patients With Bipolar I Disorder
The purpose of this study is to determine the safety and efficacy of topiramate in adolescents with manic or mixed episodes of Bipolar I Disorder.
- Conditions
- Bipolar Disorder, Affective Disorders, Psychotic, Mood Disorders, Mental Disorders
- Trial name
- NCT00035802
- Testing
- Topiramate
- Volunteers
- 13 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
Evaluation of a Cognitive Adaptive E-treatment in Schizophrenia-diagnosed Adults
This study is a multi-site, double-blind, randomized, controlled clinical trial to assess the safety and effectiveness of plasticity-based, adaptive, computerized-based cognitive remediation treatment versus a computer-based…
- Trial name
- e-CAeSAR (NCT01422902)
- Testing
- Plasticity-based Cognitive Training, Non-plasticity-based Training
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- Posit Science Corporation
Schizophrenia, Bipolar Disorder
Olanzapine Treated Adolescents With Schizophrenia or Bipolar I Disorder
The purpose of this study is to characterize olanzapine pharmacokinetics: the inter- and intra- subject variabilities of olanzapine pharmacokinetics; and the potential influence of patient factors such as age, weight, gender…
- Trial name
- NCT00113594
- Testing
- Olanzapine
- Where
- 17 sites in United States, Puerto Rico and 1 more
- Volunteers
- 100 people
- Sponsor
- Eli Lilly and Company
Schizophrenia
Study to Evaluate Safety & Efficacy of NaBen® as Add-on Treatment for Schizophrenia in Adults
The proposed Phase IIb/III study is designed to evaluate the safety and efficacy of NaBen® in improving the symptoms of schizophrenia in adults.
- Trial name
- NCT02261519
- Testing
- NaBen®
- Where
- United States
- Volunteers
- 280 people
- Sponsor
- SyneuRx International (Taiwan) Corp
Schizophrenia
A Study to Evaluate Symptomatic Remission in Schizophrenia With Long Acting Risperidone Microspheres
The purpose of this study is to evaluate symptomatic remission rate in patients with schizophrenia using long acting risperidone microspheres
- Trial name
- NCT00216528
- Testing
- risperidone
- Volunteers
- 527 people
- Sponsor
- Janssen Korea, Ltd., Korea
Schizophrenia
Pediatric Schizophrenia Efficacy and Safety Study
Efficacy and Safety study of Lurasidone in pediatric patients.
- Trial name
- NCT01911429
- Testing
- Lurasidone 40 mg, Lurasidone 80 mg
- Where
- 90 sites in United States, Belgium and 15 more
- Volunteers
- 327 people
- Sponsor
- Sumitomo Pharma America, Inc.
Schizophrenia
Safety and Efficacy of an Anti-Psychotic in Patients With Schizophrenia
The purpose of this study is to determine the efficacy (how well the drug works), safety, and side effects of paliperidone palmitate injection compared to placebo in the treatment of the symptoms of schizophrenia in adults.
- Trial name
- NCT00074477
- Testing
- R092670
- Volunteers
- 250 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Metabolic Syndrome, Schizophrenia
A Phase 4 Study to Assess the Effects of Aripiprazole Versus Other Atypical Antipsychotics in the Treatment of Schizophrenic Patients With Metabolic Syndrome
258 patients who have been treated for at least 3 months with oral olanzapine, risperidone or quetiapine in the treatment of schizophrenia and currently presenting with metabolic syndrome, will be randomized to: i) aripiprazole…
- Trial name
- NCT00508157
- Testing
- Aripiprazole, Continued Antipsychotic (Risperidone or Quetiapine or Olanzapine)
- Where
- 30 sites in Belgium, Czechia and 7 more
- Volunteers
- 125 people
- Sponsor
- Bristol-Myers Squibb
Schizophrenia
A Study of Usage of Paliperidone Palmitate in Patients With Schizophrenia in a Hospital Setting
The purpose of this study to evaluate safety, tolerability, treatment outcomes, appropriate use and pattern of paliperidone palmitate usage in participants with schizophrenia in the hospital setting.
- Trial name
- HOSPIPalm (NCT01926912)
- Testing
- No intervention
- Where
- 39 sites in Belgium, Bulgaria and 6 more
- Volunteers
- 371 people
- Sponsor
- Janssen-Cilag International NV
Schizophrenia
Bioequivalence Study of Long-Acting Paliperidone Palmitate in Patients With Schizophrenia
This multicenter, randomized, open-label, parallel-group, multiple-dose study is designed to evaluate the bioequivalence, at pharmacokinetic steady state, of a paliperidone palmitate injection manufactured by CSPC Zhongnuo…
- Trial name
- NCT07268430
- Testing
- Paliperidone Palmitate Injection(PP1M), Paliperidone Palmitate Injection(PP1M)(Reference Group)
- Where
- China
- Volunteers
- 256 people
- Sponsor
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Schizophrenia
A Study of Flexibly Dosed Paliperidone Extended Release Tablets in Participants With Schizophrenia
The purpose of this study is to evaluate the effectiveness of paliperidone extended-release (ER; designed to slowly release a drug in the body over an extended period of time) tablets in participants with schizophrenia…
- Trial name
- NCT01541371
- Testing
- Paliperidone ER
- Volunteers
- 405 people
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Schizophrenia
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
This study aims to evaluate whether PF-02545920 is safe and effective in the treatment of sub-optimally controlled symptoms of schizophrenia during a 12-week outpatient treatment period.
- Trial name
- NCT01939548
- Testing
- PF-02545920
- Where
- 44 sites in United States
- Volunteers
- 240 people
- Sponsor
- Pfizer
Schizophrenia
A Study to Assess Learning Performance in Patients With Schizophrenia and Young and Elderly Healthy Volunteers
The purpose of this study is to measure and contrast implicit and explicit learning performance in patients with schizophrenia relative to young and elderly healthy volunteers.
- Trial name
- NCT01788436
- Testing
- Cognitive Test Battery 1, Cognitive Test Battery 2
- Where
- Belgium
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.